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Abstract
Background: Studying patients with rare Mendelian diabetes has uncovered mo-
lecular mechanisms regulating β‐cell pathophysiology. Previous studies have shown 
that Class IIa histone deacetylases (HDAC4, 5, 7, and 9) modulate mammalian pan-
creatic endocrine cell function and glucose homeostasis.
Methods: We performed exome sequencing in one adolescent nonautoimmune diabetic 
patient and detected one de novo predicted disease‐causing HDAC4 variant (p.His227Arg). 
We screened our pediatric diabetes cohort with unknown etiology using Sanger sequenc-
ing. In mouse pancreatic β‐cell lines (Min6 and SJ cells), we performed insulin secretion 
assay and quantitative RT‐PCR to measure the β‐cell function transfected with the de-
tected HDAC4 variants and wild type. We carried out immunostaining and Western blot 
to investigate if the detected HDAC4 variants affect the cellular translocation and acetyla-
tion status of Forkhead box protein O1 (FoxO1) in the pancreatic β‐cells.
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1 |  INTRODUCTION
About 3% of diabetic patients involve single‐gene mutations 
(Mendelian) that may also cause type 2 diabetes (Yang & 
Chan, 2016). More than twenty genes highly expressed in 
pancreatic β‐cells have been identified within these mono-
genic subtypes (Alkorta‐Aranburu et al., 2014). Recently, 
two national surveys revealed that most patients with mono-
genic diabetes are likely to be unrecognized and misdiag-
nosed as type 1 or type 2 diabetes (Delvecchio et al., 2017; 
Johansson et al., 2017). Genetic diagnosis leads to improved 
treatment, better prediction of disease prognosis and pro-
gression, genetic counseling, and possibly prevention. The 
benefit of a molecular genetic diagnosis has been shown in 
the patients with monogenic diabetes caused by a mutation in 
the ABCC8, KCNJ11, HNF1A, or HNF4A; all these patients 
were sensitive to sulfonylureas, which greatly improved gly-
cemic control and quality of life (Hattersley & Patel, 2017). 
However, patients with a mutation in GCK typically do not 
require pharmacological intervention (Ajjan & Owen, 2014). 
Therefore, identification of novel disease‐related loci may 
provide further opportunities to derive new drug targets.
Histone deacetylases (HDACs) have a broad impact on the 
development of human disease by regulating histone modi-
fication and gene transcription (Mathias, Guise, & Cristea, 
2015; Mielcarek, Zielonka, Carnemolla, Marcinkowski, & 
Guidez, 2015). Class II HDAC4, 5, 7, and 9 modulate en-
docrine cell function and glucose homeostasis in skeletal 
muscles, adipose tissue, and liver (Daneshpajooh et al., 2017; 
Lenoir et al., 2011; Mathias et al., 2015; Mihaylova et al., 
2011). In addition, HDAC4 was also found to be a key reg-
ulator controlling the pancreatic β/δ lineage during embryo-
genesis (Lenoir et al., 2011). Makinistoglu et al. found that 
in osteoblast‐specific Hdac4 gene‐deleted (/) mice, HDAC4 
regulates not only the spatial learning and memory, male fer-
tility, and appetite, but also glucose metabolism through its 
expression in osteoblasts. They observed that the insulin con-
tent and β‐cell area in the pancreas, as well as insulin levels 
and insulin secretion in the circulation blood, were signifi-
cantly decreased in Hdac4osb / compared with the control 
littermates (Makinistoglu & Karsenty, 2015), indicating that 
HDAC4 regulates insulin content, secretion, and sensitivity 
through direct or indirect pathways. In humans, HDAC4 was 
found to be expressed in the pancreas as well, and associated 
with type 2 diabetes (Rani et al., 2017).
We report three pediatric hyperglycemic patients harbor-
ing individual HDAC4 (OMIM: 605314) mutations. These 
HDAC4 variants decreased the insulin secretion and down‐
regulated the key β‐cells transcriptional factors of pancreatic 
β‐cells. Furthermore, deacetylation of FoxO1 was inhibited 
by these HDAC4 mutations resulting in FoxO1 acetylation 
and nuclear exporting, therefore decreasing β‐cell functions.
2 |  PATIENTS AND METHODS
2.1 | Ethical compliance
The Charité committee on human subjects’ research ap-
proved the study (EA‐No EA2/054/11) and written informed 
consent was obtained.
2.2 | Patients
All individuals with hyperglycemia tested negative for β‐
cell autoantibodies and developed diabetes before the age 
of 18 years. They were recruited from Charité and interna-
tional diabetes centers. We excluded mutations in known 
genes causing monogenic diabetes (GCK, HNF4A, HNF1A, 
HNF1B, ABCC8, KCNJ11, and INS) by Sanger sequencing.
2.3 | Variants discovery with exome 
sequencing and Sanger sequencing
We conducted exome sequencing in one patient and his 
healthy parents and analyzed the sequencing results with 
our reported pipeline (Kuhnen et al., 2014) for rare de novo 
Results: We discovered three HDAC4 mutations (p.His227Arg, p.Asp234Asn, and 
p.Glu374Lys) in unrelated individuals who had nonautoimmune diabetes with vari-
ous degrees of β‐cell loss. In mouse pancreatic β‐cell lines, we found that these three 
HDAC4 mutations decrease insulin secretion, down‐regulate β‐cell‐specific tran-
scriptional factors, and cause nuclear exclusion of acetylated FoxO1.
Conclusion: Mutations in HDAC4 disrupt the deacetylation of FoxO1, subsequently 
decrease the β‐cell function including insulin secretion, resulting in diabetes.
K E Y W O R D S
diabetes, FoxO1, HDAC4 mutations, pancreatic β‐cells
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variants (Table S1) against the available databases using the 
Agilent SureSelect Human All Exon Kit (Agilent SureSelect 
v4, 50 Mb) and next‐generation sequencing (Hiseq, Illumina, 
USA). We confirmed the HDAC4 (NG_009235.1) mutation 
(p.H227R) by Sanger sequencing only in this patient, but 
not in his parents and other 200 healthy controls (Applied 
Biosystems, USA). In addition, through screening our 
diabetic cohort of 94 patients with the unknown origin for 
HDAC4 mutations (Table S2), we detected two other indi-
vidual heterozygous HDAC4 mutations in two unrelated 
families (p.D234N & p.E374K).
2.4 | Mutagenesis and transfection
The human Flag‐tagged HDAC4 cDNA (pcDNA3 N‐Flag) 
was kindly provided by Prof. Jens Fielitz of Charite. We se-
quenced the cDNA clones before the experiments, confirm-
ing the HDAC4 cDNA and the tagged Flag sequences. We 
performed mutagenesis with the primers (Table S2) designed 
for all the three mutations (p.H227R, p.D234N, p.E374K) ac-
cording to the manufacturer's instruction (QuikChange II Site‐
Directed Mutagenesis Kit, Agilent Technologies, USA). We 
extracted plasmid DNA using Qiagen kits: QIAprep® Spin 
Miniprep Kit (minipreps) and QIAfilterTM Plasmid Maxi 
Kit (Maxipreps) according to the manufacturer's instruction 
(QIAGEN, Germany). We transfected the HDAC4 constructs 
and the empty vector into the SJ pancreatic β‐cells (Jia et al., 
2015) using AmaxaTM Cell Line NucleofectorTM Kit V and 
AmaxaTM NucleofectorTM 2b device with transfection ef-
ficiency of 80%–90% (Lonza, Switzerland, Figure S1a), and 
transfected the HDAC4 constructs into MIN6 cells with lipo-
fectamine 2000 reagents with transfection efficiency of 70% or 
more (#11668027, Thermofisher, USA, Figure S1b). All the 
constructs were screened with Sanger sequencing to ensure of 
the only pointed mutations before further investigation.
2.5 | Insulin secretion assay
The glucose‐sensitive mouse β‐cell line SJ β‐cells were cul-
tured and insulin‐secretion assay was performed as reported 
earlier (Jia et al., 2015). In brief, insulin secreted into me-
dium and from whole cell lysates was quantified with Mouse 
High Range Insulin ELISA kit, according to the manufactur-
er's protocol (Alpco, USA). Cells were incubated for 30 min 
with low (3.3 mmol/L) or high (16.7 mmol/L) glucose con-
centration. We normalized secreted insulin by the total cellu-
lar protein. All the values were expressed in relation to cells 
transfected with wild‐type human HDAC4.
2.6 | Quantitative RT‐PCR
We checked the mRNA expression levels of key markers for 
pancreatic β‐cells using SYBR® Green chemistry (Applied 
Biosystems, USA) with the according primers (Table S3). 
Key factors for β‐cells function and maintenance include 
Pdx1, Neurod1, Foxa2, Hnf1α, Hnf1β, Hnf4α, Nkx6.1, 
MafA, FoxO1, Scl2a2, Abcc8, Kcnj11, Ins1, Ins2, and Gck.
2.7 | Immunoblotting (IB), 
immunofluorescence (IF), and 
immunoprecipitation (IP)
Immunoblotting and immunofluorescence staining were 
carried out as previously described (Jing et al., 2011). 
Immunoprecipitation was performed using Dynabeads 
Protein A Immunoprecipitation Kit according to the manufac-
turer's protocol (#10006D, Thermofisher, USA). Antibodies 
used in this study: HDAC4 (#7628, Cell signaling, Germany), 
FoxO1 (#2880, Cell signaling, Germany), Pdx1 (sc‐14664, 
Santa Cruz, USA), acetylated lysine (#9441, Cell signaling 
Germany), α‐Tubulin (#T6199, Sigma, USA), and total his-
tone H3 (#4499, Cell signaling, Germany) (Table S4).
We used GraphPad Prism 5.0 software (GraphPad 
Software). Differences between three or more groups were 
assessed by 1‐way ANOVA with Dunnett's correction. 
p < 0.05 were considered significant.
3 |  RESULTS
3.1 | Patients with defective insulin secretion 
harbor HDAC4 mutations
Our first patient developed a large pubic abscess at the age 
of 15 years. Hyperglycemia and elevated HbA1c were no-
ticed (Figure 1a, left and Table 1). He received multiple daily 
insulin injections but discontinued insulin after an intended 
weight loss (Figure 1a, left). Insulin was then reinstituted 
after an increase in HbA1C. At the age of 19 years, he skipped 
insulin injections and developed ketoacidosis (Figure 1a, left 
and Table 1).
We performed exome sequencing in the patient and his 
healthy parents. From the 34 de novo heterozygous variants, 
eight variants were functionally predicted to be disease caus-
ing by multiple in‐silico predictive algorithms (Table S1). We 
focused on HDAC4 due to its specific expression pattern and 
roles in pancreatic islet development (Lenoir et al., 2011), 
gluconeogenesis, and insulin resistance (Mathias et al., 2015; 
Mihaylova et al., 2011). We confirmed the novel heterozy-
gous HDAC4 mutation solely in the patient (Hg19, chr2: 
240,078,401, T > C, H227R > p.H227R, novel in the gno-
mAD database, Figure 1a, right, and Table 1), but not in his 
parents and in additional 200 healthy controls. The mutation 
was not observed in 138,496 alleles in the gnomAD database 
and is predicted to probably damage the protein structure, 
function, protein–protein interaction, or to interfere with the 
conservation with multiple lines of computational algorithms 
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(Table 1). Therefore, this variant is likely pathogenic to the 
glucose metabolism according to the American College of 
Medical Genetics and Genomics (ACMG) guideline of the 
sequence variants (Richards et al., 2015). After screening 
our cohort of 94 patients for HDAC4 mutations (Table S2), 
we identified two more HDAC4 mutations in two unrelated 
hyperglycemic individuals (Figure 1b,c), these two variants 
were not detected in the 200 healthy individuals either.
The second patient had hyperglycemia (> 400 mg/dl) 
and a highly elevated HbA1c level (Table 1) at the age of 
8.6 years. Multiple daily insulin injections were begun. He 
carried an HDAC4 mutation (Hg19: chr2: 240078381, G>A. 
p.H234N, rs549858743, MAF in the European population: 
0/126708 in the gnomAD database, Figure 1b), which was 
not found in any other patients of our cohort. Unfortunately, 
his parents were not available for genetic testing.
The third patient came from a large Türkish kindred and 
was investigated because of high diabetes prevalence in 
this family and her persistent fasting hyperglycemia. She 
exhibited slightly increased fasting glucose (110–120 mg/
dl) and HbA1c levels when she was 6 years old (Table 1). 
Her now 33‐year‐old mother was obese (BMI: 33.3 kg/m2), 
had increased fasting glucose (110–120 mg/dl) since pu-
berty, gestational diabetes during pregnancy, but was man-
aged since then with diet alone (Figure 1c). The maternal 
grandmother had gestational diabetes that progressed to 
type 2 diabetes at the age of 32 years. She had required 
insulin and died at the age of 49 years from myocardial 
F I G U R E  1  Mutations in HDAC4 are present in pediatric hyperglycemic patients. a. The disease progress of the first patient and the de novo 
HDAC4 mutation (p.H227R) found in the affected patient. DKA: diabetic ketoacidosis. b. Sporadic patient 2 carried one heterozygous mutation 
(p.D234N) in HDAC4. c. The studied Turkish family presented as early onset of diabetes (age 30–40 years) and obesity carried one heterozygous 
mutation (p.E374K) in HDAC4. Solid symbols illustrate affected individuals, open symbols illustrate unaffected individuals. Squares illustrate male 
subjects and circles illustrate female subjects; a diagonal line through a symbol represents a deceased individual; arrow indicates the index patient. 
Under the symbols: diagnosis, treatment, and body mass index (BMI) of the affected individuals were shown vertically. T2D: type 2 diabetes, GD: 
gestational diabetes, Oral: oral drug administration, IFG: impaired fasting glucose d. Schematic representation of the HDAC4 protein domains and 
its established binding sites (MEF2s), nuclear localization signal (NLS1, NLS2) in the N‐terminal part; a highly conserved deacetylase domain, a 
nuclear export signal (NES) at the C‐terminal end, three 14‐3‐3 binding sites, and other regulatory sites (phosphorylation, Sumoylation or oxidation 
sites, binding sites for nuclear import, as well as nitric oxide synthase). The locations and character of the HDAC4 mutations, modified from 
Mielcarek et al (Mielcarek et al., 2015)
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infarction. Overall, six sisters of the maternal grandmother 
were diagnosed with type 2 diabetes at ages between 30 
and 40 years, of whom three had been treated with insu-
lin (for 3–10 years) and three were treated with oral an-
tihyperglycemic drugs. All were obese (BMI: 35–45 kg/
m2). We found one heterozygous HDAC4 mutation in this 
family (Figure 1c and Table 1), which is relatively rare in 
the European population (Hg 19: chr2: 240056115 G>A, 
E374K>p.E374K, rs370963321, MAF in the European 
population: 1/27,424 in the gnomAD database).
All three detected variants localize at the N‐terminal region 
of the HDAC4 protein, which harbors cleavage and phosphor-
ylation sites (Mielcarek et al., 2015), suggesting this region as 
an important regulatory HDAC4 domain (Figure 1d).
3.2 | HDAC4 mutations disrupt 
insulin secretion and down‐regulate 
transcription factors
We transfected wild‐type and the three mutated HDAC4 
constructs into glucose‐sensitive mouse SJ β‐cells (Jia et 
al., 2015). Insulin secretion was significantly decreased by 
the three HDAC4 mutations compared to wild‐type HDAC4 
in both low (3.3 mmol/L) and high glucose (16.7 mmol/L) 
levels (Figure 2a). To examine the effects of each of the 
HDAC4 mutations on the expression of key factors in β‐cells 
(Table S3), we performed quantitative RT‐PCR and found 
that expression of FoxO1, Pdx1, Neurod1, and Gck was sig-
nificantly down‐regulated by each of the three HDAC4 muta-
tions, compared to wild‐type HDAC4 (Figure 2b). For Hnf4a 
and Foxa2, down‐regulation could only be achieved by the 
two HDAC4 p.H227R and p.D234N mutations, but not by the 
p.E374K mutation, corresponding to the milder phenotypes 
in the third patient’s family. The regulation of the transcrip-
tion factors of FoxO1, Pdx1, Neurod1, and glucokinase, Gck, 
by the HDAC4 mutations were repeatedly detected irrespec-
tive of transfection times (48 and 72 hr) or cell batches.
3.3 | HDAC4 mutations inhibit nuclear 
FoxO1 translocation
FoxO1 is translocated into the nuclear when deacetylated 
by SIRT1, induces the NeuroD1 and MafA expression and 
thus protects against pancreatic β failure (Kitamura et al., 
2005). To investigate whether or not cellular translocation 
of FoxO1 is critically influenced by our diabetes‐associated 
Patient ID Patient 1 Patient 2 Patient 3
Gender Male Male Female
Ethnicity German German Turkish
Family history Parents healthy Unknown Mother diabetes (diet), grandmother mother side 
diabetes (insulin)
Diabetes onset (years) 14.9 8.6 6.3 (IFG)
Initial glucose (mg/dl) 293 (random) >400 (random) 110 (fasting)
Initial HbA1c (%) 10.4 11.0 5.9
HOMA‐IR n.a. n.a. 2.6 (elevated for prepubertal)
BMI (kg/m2) 30.1 18.2 16.1
BMI‐SDS +2.3 +0.6 0.48
Antibodiesa Negative Negative Negative
Diabetes treatment Initial MDI insulin, off 
insulin age 17.2–18.4, 
continued NPH insulin 
alone
Insulin (pump), no 
remission
Diet
g.Pos (Hg19) 2:240078401 T>C 2:240078381 C>T 2:240056115 C>T
c.posb c.680A>G c. 700 G>A c. 1120 G>A
Zygosity Heterozygous Heterozygous Heterozygous
Ref.SNP (MAF) Novel rs549858743 (0.0002)c rs370963321 (3.13e−5)
Function change p.H227R p.D234N p.E374K
Predictiond Disease causing Disease causing Disease causing
Note. AA, amino acid: MAF, minor allele frequency from ExAc database; NA, not available; IFG, impaired fasting glucose; g.Pos, genomic position; c.Pos, coding 
position.
aAntibodies tested: IA‐2, GAD65, IAA. bNM_006037.3. cIt is novel in the European population. dClassified as pathogenic in Polyphen, SIFT, Mutation Taster, GERP++, 
and LRT. 
T A B L E  1  Clinical characteristics of patients with heterozygous HDAC4 mutations
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HDAC4 mutations, we transfected wild‐type and three mu-
tated HDAC4s (p.H227R, p.D234N, p.E374K) into mouse 
MIN6 β‐cells and examined FoxO1 with immunostaining. 
We found that the three HDAC4 mutations promoted both 
HDAC4 and FoxO1 nuclear exclusion, compared to wild‐
type HDAC4 (Figure 3a). To further validate the FoxO1 
cellular translocation, we separated cytosol proteins from 
the nuclear in MIN6 cells. Subsequently, immunoblotting 
specifically demonstrated that all three HDAC4 mutations 
prevented translocation of FoxO1 from a cytoplasmic into 
a nuclear fraction in the mouse β‐cells (Figure 3b). The ex-
periments were replicated with different transfection time 
as well as with different batches of MIN6 and SJ β‐cell 
lines (Figure S2a,b), respectively. However, the PDX1 cel-
lular location was not affected by the HDAC4 mutations in 
pancreatic β‐cells (Figure S2c).
3.4 | HDAC4 mutations specifically fail to 
deacetylate FoxO1 in pancreatic β‐cells
Acetylated FoxO1 is primarily cytoplasmic, when fully 
deacetylated, it lingers in the nuclear and protects β‐cell 
function (Kim‐Muller et al., 2016). To investigate whether 
or not the HDAC4 mutations fail to deacetylate FoxO1, 
we performed immunoprecipitation with specific antibod-
ies against FoxO1 and measured acetylated‐lysine level 
by western blot analysis. Interestingly, we observed that 
acetylated FoxO1 dramatically increased if cells were ex-
posed to diabetes‐associated HDAC4 mutations, compared 
to wild‐type HDAC4, while there was no much change 
in total FoxO1 protein level (Figure 3c). These results 
indicate that FoxO1 is a deacetylation target of HDAC4 
and diabetes‐associated HDAC4 mutations show a selec-
tive impaired ability to deacetylate FoxO1 in pancreatic 
β‐cells.
4 |  DISCUSSION
We detected a de novo HDAC4 p.H227R variant by 
exome sequencing in a diabetic child and afterward de-
tected two young hyperglycemic individuals harbor-
ing independent HDAC4 variants (p.D234N, p.E374K). 
Though the latter two variants have been shown in the 
population of Asian in both gnomAD and ExAC data-
bases (p.D234N: 13/18870 in East Asian, 17/277220 in 
all populations; p.E374K: 139/30660 in South Asian; 
149/242078 in all populations), the frequencies of which 
are quite rare in the European population (In non‐Finnish 
European D234N: 0/126708; p.E374K: 4/109696), which 
are very likely due to population heterogeneity or the 
possibility of incomplete penetrance. The incomplete 
penetrance for severe Mendelian childhood disorders is 
likely more common than previously believed, even with 
homozygous variants in the candidate genes with strong 
confidence for the relevant disorders (Chen et al., 2016). 
This state‐of‐affair could be due to the combination of 
factors, such as expression patterns of normal alleles, 
epigenetic modification, genetic drift, and specific popu-
lation genetic variant modifiers, or environmental modi-
fiers (Cooper, Krawczak, Polychronakos, Tyler‐Smith, & 
Kehrer‐Sawatzki, 2013).
F I G U R E  2  HDAC4 mutations 
impair β‐cell function. a. Insulin secretion 
in mouse SJ β‐cells was suppressed by 
transfection with three mutated HDAC4 at 
both low (3.3 mmol/L) and high glucose 
levels (16.7 mmol/L) compared to that in 
the cells transfected with wild‐type HDAC4. 
Technical replications =4, biological 
replications =4. b. Pancreatic β‐cell‐specific 
transcriptional and regulatory factors were 
down‐regulated by the mutated HDAC4. 
Statistical analyses were performed using 
GraphPad Prism 5.0 software. *: p < 0.05, 
**:p < 0.01, ***: p < 0.001, ns: not 
significant
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The utility of publicly available databases such as gno-
mAD or ExAC as controls has limitations since both these 
databases contain many type 2 diabetes cohorts (http://gno-
mad.broadinstitute.org/about). Most cases of monogenic 
diabetes were often misdiagnosed as having type 2 or type 
1 diabetes (Delvecchio et al., 2017; Johansson et al., 2017). 
Furthermore, Mendelian diabetes mutations were previously 
thought to be highly penetrant, but were found to have reduced 
or incomplete penetrance, and therefore can be identified 
more frequently in age‐matched normoglycemic individuals 
compared with other highly penetrant mutations (Patel et al., 
2017). The reduced penetrance of the mutation is important 
to genetic counseling of at‐risk relatives undergoing predic-
tive tests because the chance of presenting with diabetes is no 
longer based simply on the odds of inheriting the mutation. 
Not all heterozygous persons will develop diabetes, and those 
that do are likely to have a later onset. Therefore, individu-
als harboring the specific mutation could be encouraged to 
perform preventive strategies such as healthier lifestyle. We 
have a similar scenario of our third hyperglycemia family. 
The index child showed slight hyperglycemia; her mother 
and mother‐side grandmothers all showed either gestational 
diabetes and/or early‐onset type 2 diabetes. Even though the 
HDAC4 p.E374K variant in this family has a relatively high 
allele frequency of the South Asian, the allele frequency in 
European is quite rare, indicating both population hetero-
geneity and the incomplete penetrance of this variant to the 
hyperglycemia.
Our functional analysis revealed that the three detected 
HDAC4 variants could disrupt the mature β‐cells to secrete 
insulin in both statuses of basic and high glucose concentra-
tion. The decreased β‐cell function was due to the down‐reg-
ulation of the vital transcriptional or glucose transport factors 
by the HDAC4 variants. So far, there are only a few studies 
focusing on the association for HDAC4 and the function of 
the pancreas and/or islets (Lenoir et al., 2011; Makinistoglu 
& Karsenty, 2015). During embryogenesis, overexpression 
of HDAC4 and HDAC5 showed a decreased pool of insulin‐
producing β‐cells and somatostatin‐producing δ‐cells (Lenoir 
et al., 2011). In contrast, the osteoblast‐specific Hdac4 
F I G U R E  3  HDAC4 mutations export FoxO1 from nuclear to cytosol through increasing levels of acetylation in Min6 cells. a. 
Immunostaining of DAPI (blue), HDAC4(red), and FoxO1 (green) in MIN6 cells that were transfected with wild‐type (WT) or three mutated 
HDAC4 (p.H227R, p.D234N, and p.E374K). Both HDAC4 (left) and FoxO1 (right) were translocated into the cell cytosol in the mutated 
HDAC4 transfected cells compared to the wild type of HDAC4 transfected cells. b. Immunoblotting with antibodies against FoxO1, α‐Tubulin, 
and Histone 3 (H3) of lysates separately extracted from nuclear (left) and cytosol (right) of MIN6 cells that were transfected with wild‐type 
(WT) or three mutated HDAC4 (p.H227R, p.D234N and p.E374K). c. Immunoblotting with antibodies against acetylated‐lysine FoxO1, and 
α‐Tubulin using anti‐FoxO1 immunoprecipitation lysates of MIN6 cells that are transfected with wild‐type (WT) or three mutated HDAC4 
(p.H227R, p.D234N, and p.E374K)
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knock‐out mice showed decreased β‐cell area as well as in-
sulin contents in the pancreas, and decreased insulin secre-
tion in the blood (Makinistoglu & Karsenty, 2015). Recently, 
HDAC4 was found to be one of the protective genes for type 
2 diabetes in human (Rani et al., 2017).
How HDAC4 operates to influence insulin secretion in 
the pancreas is a question that requires further detail investi-
gation. From this report, we showed that the post‐transcrip-
tional regulation (deacetylation) of FoxO1 was affected by 
the variants of HDAC4 in patients, the endogenous HDAC4 
expression and its enzyme activity remained unchanged (data 
not shown). The HDAC4 variants, therefore, very likely cause 
the FoxO1 deacetylation failure, results in FoxO1 acetylation 
and nuclear exclusion, therefore, disrupts β‐cell function and 
maintenance (Figure 3). The diverse severity of clinical fea-
tures; from severe hyperglycemia (p.H227R & p.D234N) to 
the modest IFG (p.E374K) matches their responding func-
tional abnormality from different variants (Figure 2ab). All 
the above‐mentioned evidence supports that these pathogenic 
variants cause hyperglycemia according to the guideline of 
The American College of Medical Genetics and Genomics 
(ACMG) (Richards et al., 2015).
HDAC4 haploinsufficiency was reported to result in a 
severe brachydactyly mental retardation syndrome. The syn-
drome includes a variety of clinical features, such as brachy-
dactyly E, developmental delays, behavioral problems, and 
obesity in 80% of the patients. However, the glucose levels 
were not reported (Williams et al., 2010). Mihaylova et al. 
found that HDAC4/5 recruit HDAC3 resulting in promoter 
induction of gluconeogenesis enzymes such as G6Pase, con-
trols the FOXO acetylation in hepatocytes and liver; contrib-
ute to the hyperglycemic phenotype of type 2 diabetic rodent 
models in their insulin‐resistant states (Mihaylova et al., 
2011). Similarly, in skeletal muscle cells, HDAC4 down‐reg-
ulates genes involved in energy expenditure, results in insulin 
resistance and type 2 diabetes (Fang et al., 2016). Moreover, 
Hdac4 suppressed transcription of Glut4, a key protein for 
glucose uptake in adipocytes (Henriksson et al., 2015), and 
disruption of Hdac4 in macrophages is sufficient to promote 
insulin resistance and obesity (Luan et al., 2014). From this 
report, obesity is present in two of the three hyperglycemic 
families, and the detected HDAC4 variants are missense vari-
ants instead of HDAC4 haploinsufficiency. Our first patient 
was severely obese and his glucose levels were improved with 
the loss of weight. For the third family, the mother and seven 
mother‐side grandmothers of the index patient are present as 
severe obesity and type 2 diabetes, even though the index pa-
tient is currently slim very likely due to the young age, she 
showed slightly insulin resistance (Table 1). The pathogenic 
roles of HDAC4 in hyperglycemia, and/or, obesity should be 
thus systematically investigated in the near future.
Except for its critical regulatory role of insulin signaling 
in liver (Langlet et al., 2017), FoxO1 maintains β‐cell mass 
(Kitamura et al., 2002; Okamoto et al., 2006), β‐cell identity, 
and proper β‐cell function (Kawamori et al., 2006; Talchai, 
Xuan, Kitamura, DePinho, & Accili, 2012). Impaired FoxO 
activity causes MODY‐like diabetes through the reduced met-
abolic flexibility of β‐cells (Kim‐Muller et al., 2014). FoxO1 
transcriptional activity is regulated by a complex array of post‐
translational modifications, one of the key events in regulating 
FoxO1 activity in β‐cells is the acetylation of specific lysine 
residues. When fully acetylated, FoxO1 exports from nuclear 
to the cytoplasm, whereas fully deacetylated, it imports into the 
nuclear and increases its transcriptional activity. In addition, the 
acetylation of FoxO1 increases the levels of its phosphorylation, 
resulting in its cytoplasm translocation and down‐regulation of 
the expression of the target genes (Matsuzaki et al., 2005).
Deacetylated FoxO1 protects β‐cell function by limiting mi-
tochondrial lipid utilization through decreasing fatty acid oxida-
tion and enhancing insulin secretion in the context of diabetes 
(Kim‐Muller et al., 2016); which is in consist in the findings 
that the levels of acetylated FoxO1 are markedly increased in 
pancreatic tissues of diabetic, compared to healthy rats (Ding et 
al., 2014). We found elevated levels of acetylated FoxO1 in the 
pancreatic β‐cells exposed to the HDAC4 mutations compared 
to the wild type, indicating the failure of FoxO1 deacetylation in 
the diabetic patients. (Zhang et al., 2016) revealed that FoxO1 
plays an important role in regulating β‐cell compensation for 
insulin resistance to maintain euglycemia in obesity; FoxO1 
acts in parallel with Pdx1 in nuclear of β‐cells and colocalize in 
human fetal islets, in contrast to the assertion that FoxO1 coun-
teracts Pdx1 by promoting Pdx1 nuclear exclusion in β‐cells 
(Kawamori et al., 2006). In this report, we found dramatically 
increasing levels of acetylation FoxO1 and obvious nuclear 
export of both HDAC4 and FoxO1, but the location of Pdx1 
remains unchanging, indicating the HDAC4 mutations disrupt 
the deacetylation of FoxO1, but not the pdx1. We therefore hy-
pothesize FoxO1 is deacetylated not only by Sirt1, Sirt2, and 
Sirt6, but also by HDAC4 in the pancreas (Daitoku et al., 2004; 
Kim‐Muller et al., 2016; Kitamura et al., 2005; Song, Wang, 
Ka, Bae, & Park, 2016). The regulation of FoxO1 to β‐cell 
compensation to overnutrition and obesity (Zhang et al., 2016) 
was thereafter disrupted by the FoxO1 deacetylation failure in 
the diabetic patients harboring HDAC4 mutations. How these 
mutations cause deacetylation failure of the FoxO1 and further 
affects the β‐cell function changing should be investigated in 
the subsequent studies.
In summary, we detected three HDAC4 variants (de novo, 
and with incomplete penetrance) in three separate hypergly-
cemic families with/without obesity. In pancreatic β‐cells, 
these variants were found to decrease the insulin secretion 
and down‐regulate the pancreatic β‐cells key factors. In 
the mechanism, the β‐cells dysfunction might be caused 
by the FoxO1 deacetylation failure due to the HDAC4 mu-
tations. The functional evidence in combination with what 
was reported in previous animal model studies: the FoxO1 
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deacetylation affects the function of β‐cells, clearly shows 
that the HDAC4 mutations are likely pathogenic of childhood 
hyperglycemia, and the HDAC4 variants cause childhood hy-
perglycemia with at least limited or even moderate evidence 
(Strande et al., 2017). Our study also suggests that HDAC4‐
mediated FoxO1 deacetylation could represent a novel target 
for pharmacotherapy, not only of decreasing glucose‐sensi-
tive insulin secretion but also for insulin resistance. However, 
the complex interplay of histone modifications and hypergly-
cemia is required for further comprehensive investigation.
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